Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
GENGLYCOS
product2 mentionslast seen Nov 3, 2026
Therapy for glycogen storage disease type Ia in adult and pediatric patients eight years and older.
Relationships 3
Relationship
Ultragenyx Pharmaceutical Inc.developsGENGLYCOS
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 3, 2026Ultragenyx Pharmaceutical Inc. 8-K: Item 2.01: Completion of Acquisition or Disposition of Assets; Item 2.02: Results of Operations and Financial Condition; Item 2.05: Cost Associated with Exit or Disposal Activities; Item 9.01: Financial Statements and Exhibits
GENGLYCOS (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa)
- filingSEC EDGAROct 7, 2026Ultragenyx Pharmaceutical Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement
The Company was awarded the PRV by the U.S. Food and Drug Administration ("FDA") on August 19, 2026 upon approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401